1-2 of 2
Pierre Beauparlant, Ph.D.
Close
Sort by
Journal Articles

A Canadian Expanded Access Trial of Oral Nilotinb in Adult Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase

Robert Delage, MD, MSc, FRCP, A. Robert Turner, MD, FRCPC, Brian Leber, MD, Wanda S. Hasegawa, MD, Denis-Claude Roy, MD, Mary Lynn Savoie, MD, Heather A Leitch, MD, PhD, Isabelle Bence-Bruckler, MD, FRCPC, Donna L. Forrest, MD, Sindu Kanjeekal, MD, Sehdev Sandeep, MD, Pierre Laneuville, MD, Sarit Assouline, MD, Kuljit Grewal, MD, Michael J. Kovacs, MD, FRCPC, Wendy Lam, MD, Annie Woo, M.Sc., Pierre Beauparlant, Ph.D., Jeffrey H. Lipton, MD, PhD
Journal: Blood
Blood (2011) 118 (21): 4437.
https://doi.org/10.1182/blood.V118.21.4437.4437
Published: 2011
Journal Articles

Obatoclax (GX15-070) Is a Potent Antagonist of Constitutive Mcl-1/Bak Interactions in Intact Mitochondrial Membrane and Synergizes with Bortezomib in Mantle Cell Lymphoma.

Gordon Shore, PhD, Mark Watson, Ph.D., Anne Roulston, Ph.D., Richard Marcellus, Ph.D., Nancy Steenart, Ph.D., Pierre Beauparlant, Ph.D., Sasmita Tripathy, Ph.D., Xavier Billot, Ph.D., Laurent Bélec, Ph.D., Giorgio Attardo, Ph.D., Mai Nguyen, Ph.D., Stephane Acoca, B.Sc., Enrico Purisima, Ph.D, Patricia Pérez-Galan, Ph.D., Dolors Colomer, Ph.D.
Journal: Blood
Blood (2006) 108 (11): 832.
https://doi.org/10.1182/blood.V108.11.832.832
Published: 2006